NCT00542763View on ClinicalTrials.gov

Mycophenolate Sodium Treatment in Patients With Primary Sjogren's Syndrome

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 30, 2005

Study Completion Date

September 30, 2007

Conditions
Primary Sjogren's Syndrome
Interventions
DRUG

Mycophenolate sodium

Medical treatment is initiated with one tablet of 360 mg mycophenolate sodium orally per day for eligible patient. The dosage will be increased weekly by 360 mg up to a maximum stable dose of 1440mg daily. In patients not well tolerating the drug the dosage can be reduced to 720 mg per day.

Trial Locations (1)

48129

University Hospital Muenster, Münster

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

University Hospital Muenster

OTHER

NCT00542763 - Mycophenolate Sodium Treatment in Patients With Primary Sjogren's Syndrome | Biotech Hunter | Biotech Hunter